https://doi.org/10.4081/gh.2026.1487
Prostate cancer burden and attributable risk factors in East Asia from 1990 to 2021: a systematic analysis
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Accepted: 6 August 2026
Published: 5 October 2026
Prostate cancer is a significant health concern in East Asia, where distinctive characteristics of disease presentation and outcomes warrant focused epidemiological investigation. This study evaluated the current status, future trends and risk factors across six East Asian regions. Mortality, incidence, Disability-Adjusted Life-Years (DALYs), and age-standardized rates were estimated using data from the Global Burden of Disease Study 2021. Join point, an age-period-cohort model and decomposition analyses were applied to reflect epidemiological trends. The Autoregressive Integrated Moving Average (ARIMA) model was used to predict the burden of prostate cancer 2022-2050. Taiwan had the highest Age-Standardized Mortality Rate (ASMR: 10.83 [95% uncertainty interval [UI]: 9.48–12.18]), Age-Standardized Incidence Rate (ASIR: 37.68 [95% UI: 32.54–43.34]), and DALY rate (ASDR: 192.07 [95% UI: 170.35–214.13]) in 2021. Mortality increased with age across all regions, while the cohort effect on mortality remained stable. The effects of age, period and cohort on mortality and incidence and the percentage of aging, population and epidemiological changes in the total trend differed across regions. ARIMA projections predicted a “U”-shaped ASMR trends in Japan. The Democratic People's Republic of Korea had the highest DALYs attributable to low in milk and calcium intake, whereas smoking-related ASDR were highest in Taiwan. The prostate cancer burden in East Asia remains substantial, particularly among older populations. Although overall trends appear more favourable than global averages, several regions face concerning future prospects.
Downloads
Akiyama H, 2020. Aging well: an update. Nutr Rev 78:3–9. DOI: https://doi.org/10.1093/nutrit/nuaa084
Albers P, Bashir S, Mookerji N, Broomfield S, Martín AM, Ghosh S, Kinnaird A, 2024. Prostate Cancer Among Black Men in Canada. JAMA Netw Open 7:e2418475. DOI: https://doi.org/10.1001/jamanetworkopen.2024.18475
Aune D, Navarro Rosenblatt DA, Chan DS, Vieira AR, Vieira R, Greenwood DC, Vatten LJ, Norat T, 2015. Dairy products, calcium, and prostate cancer risk: a systematic review and meta-analysis of cohort studies. Am J Clin Nutr 101:87–117. DOI: https://doi.org/10.3945/ajcn.113.067157
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A, 2018. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68:394–424. DOI: https://doi.org/10.3322/caac.21492
Chang CM, Su YC, Lai NS, Huang KY, Chien SH, Chang YH, Lian WC, Hsu TW, Lee CC, 2012. The combined effect of individual and neighborhood socioeconomic status on cancer survival rates. PLoS One 7:e44325. DOI: https://doi.org/10.1371/journal.pone.0044325
Cooperberg MR, Broering JM, Carroll PR, 2009. Risk assessment for prostate cancer metastasis and mortality at the time of diagnosis. J Natl Cancer Inst 101;878–87. DOI: https://doi.org/10.1093/jnci/djp122
Cornford P, van den Bergh RCN, Briers E, Van den Broeck T, Brunckhorst O, Darraugh J, Eberli D, De Meerleer G, De Santis M, Farolfi A, Gandaglia G, Gillessen S, Grivas N, Henry AM, Lardas M, van Leenders GJLH, Liew M, Linares Espinos E, Oldenburg J, van Oort IM, Oprea-Lager DE, Ploussard G, Roberts MJ, Rouvière O, Schoots IG, Schouten N, Smith EJ, Stranne J, Wiegel T, Willemse PM, Tilki D. 2024. EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer-2024 Update. Part I: Screening, Diagnosis, and Local Treatment with Curative Intent. Eur Urol 86:148–63. DOI: https://doi.org/10.1016/j.eururo.2024.03.027
GBD 2019 Risk Factors Collaborators, 2020. Global burden of 87 risk factors in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet 396:1223–49.
GBD 2021 Demographics Collaborators, 2024a. Global age-sex-specific mortality, life expectancy, and population estimates in 204 countries and territories and 811 subnational locations, 1950-2021, and the impact of the COVID-19 pandemic: a comprehensive demographic analysis for the Global Burden of Disease Study 2021. Lancet403, 1989–2056.
GBD 2021 Risk Factors Collaborators, 2024b. Global burden and strength of evidence for 88 risk factors in 204 countries and 811 subnational locations, 1990-2021: a systematic analysis for the Global Burden of Disease Study 2021. Lancet403, 2162–2203.
GBD 2021 Causes of Death Collaborators, 2024c. Global burden of 288 causes of death and life expectancy decomposition in 204 countries and territories and 811 subnational locations, 1990-2021: a systematic analysis for the Global Burden of Disease Study 2021. Lancet403, 2100–2132.
GBD 2021 Diseases and Injuries Collaborators, 2024d. Global incidence, prevalence, years lived with disability (YLDs), disability-adjusted life-years (DALYs), and healthy life expectancy (HALE) for 371 diseases and injuries in 204 countries and territories and 811 subnational locations, 1990-2021: a systematic analysis for the Global Burden of Disease Study 2021. Lancet 403:2133–61.
Gray PJ, Lin CC, Cooperberg MR, Jemal A, Efstathiou JA, 2017. Temporal trends and the impact of race, insurance, and socioeconomic status in the management of localized prostate cancer. Eur Urol 71:729–37. DOI: https://doi.org/10.1016/j.eururo.2016.08.047
Han T, Chen W, Qiu X, Wang W, 2024. Epidemiology of gout - Global burden of disease research from 1990 to 2019 and future trend predictions. Ther Adv Endocrinol Metab 15:20420188241227295. DOI: https://doi.org/10.1177/20420188241227295
Hoffman KE, Penson DF, Zhao Z, Huang LC, Conwill R, Laviana AA, Joyce DD, Luckenbaugh AN, Goodman M, Hamilton AS, Wu XC, Paddock LE, Stroup A, Cooperberg MR, Hashibe M, O'Neil BB, Kaplan SH, Greenfield S, Koyama T, Barocas DA, 2020. Patient-reported outcomes through 5 years for active surveillance, surgery, brachytherapy, or external beam radiation with or without androgen deprivation therapy for localized prostate cancer. JAMA 323:149–63. DOI: https://doi.org/10.1001/jama.2019.20675
Huang D, Lai H, Shi X, Jiang J, Zhu Z, Peng J, Zhang S, Chen Y, Yu H, Zhao Q, Chen Y, Chen J, 2024. Global temporal trends and projections of acute hepatitis E incidence among women of childbearing age: Age-period-cohort analysis 2021. J Infect 89:106250. DOI: https://doi.org/10.1016/j.jinf.2024.106250
Hugosson J, Roobol MJ, Månsson M, Tammela TLJ, Zappa M, Nelen V, Kwiatkowski M, Lujan M, Carlsson SV, Talala KM, Lilja H, Denis LJ, Recker F, Paez A, Puliti D, Villers A, Rebillard X, Kilpeläinen TP, Stenman UH, Godtman RA, Stinesen Kollberg K, Moss SM, Kujala P, Taari K, Huber A, van der Kwast T, Heijnsdijk EA, Bangma C, De Koning HJ, Schröder FH, Auvinen A; ERSPC investigators, 2019. A 16-yr follow-up of the european randomized study of screening for prostate cancer. Eur Urol 76:43–51. DOI: https://doi.org/10.1016/j.eururo.2019.02.009
Ilic D, Djulbegovic M, Jung JH, Hwang EC, Zhou Q, Cleves A, Agoritsas T, Dahm P, 2018. Prostate cancer screening with prostate-specific antigen (PSA) test: a systematic review and meta-analysis. BMJ 362:k3519. DOI: https://doi.org/10.1136/bmj.k3519
Ito K, 2014. Prostate cancer in Asian men. Nat Rev Urol 11:197–212. DOI: https://doi.org/10.1038/nrurol.2014.42
Kimura K, Egawa S, 2018. Epidemiology of prostate cancer in Asian countries. Int J Urol 25;524–31. DOI: https://doi.org/10.1111/iju.13593
Li Y, Ning Y, Shen B, Shi Y, Song N, Fang Y, Ding X, 2023. Temporal trends in prevalence and mortality for chronic kidney disease in China from 1990 to 2019: an analysis of the Global Burden of Disease Study 2019. Clin Kidney J 16:312–21. DOI: https://doi.org/10.1093/ckj/sfac218
Lin PH, Chang SW, Tsai LH, Kan HC, Liu JM, Chuang CK, Pang ST, Yu KJ, 2020. Increasing incidence of prostate cancer in Taiwan: A study of related factors using a nationwide health and welfare database. Medicine (Baltimore) 99:e22336. DOI: https://doi.org/10.1097/MD.0000000000022336
Litwin MS, Tan HJ, 2017. The diagnosis and treatment of prostate cancer: a review. JAMA 317:2532–42. DOI: https://doi.org/10.1001/jama.2017.7248
Narita S, Hatakeyama S, Sakamoto S, Kato T, Inokuchi J, Matsui Y, Kitamura H, Nishiyama H, Habuchi T, 2022. Management of prostate cancer in older patients. Jpn J Clin Oncol 52:513–25. DOI: https://doi.org/10.1093/jjco/hyac016
Prentice AM, 2014. Dairy products in global public health. Am J Clin Nutr 99:1212s–6s. DOI: https://doi.org/10.3945/ajcn.113.073437
Qiu H, Cao S, Xu R, 2021. Cancer incidence, mortality, and burden in China: a time-trend analysis and comparison with the United States and United Kingdom based on the global epidemiological data released in 2020. Cancer Commun (Lond) 41:1037–48. DOI: https://doi.org/10.1002/cac2.12197
Rahmati S, Azami M, Delpisheh A, Hafezi Ahmadi MR, Sayehmiri K, 2018. Total calcium (dietary and supplementary) intake and prostate cancer: a systematic review and meta-analysis. Asian Pac J Cancer Prev 19:1449–56.
Rhee H, Vela I, Chung E, 2016. Metabolic syndrome and prostate cancer: a review of complex interplay amongst various endocrine factors in the pathophysiology and progression of prostate cancer. Horm Cancer 7:75–83. DOI: https://doi.org/10.1007/s12672-015-0238-x
Schafer EJ, Laversanne M, Sung H, Soerjomataram I, Briganti A, Dahut W, Bray F, Jemal A, 2025. Recent patterns and trends in global prostate cancer incidence and mortality: an update. Eur Urol 87:302–13. DOI: https://doi.org/10.1016/j.eururo.2024.11.013
Tomic K, Ventimiglia E, Robinson D, Häggström C, Lambe M, Stattin P, 2018. Socioeconomic status and diagnosis, treatment, and mortality in men with prostate cancer. Nationwide population-based study. Int J Cancer 142:2478–84. DOI: https://doi.org/10.1002/ijc.31272
Yeung WJ, Lee Y, 2022. Aging in East Asia: new findings on retirement, health, and well-being. J Gerontol B Psychol Sci Soc Sci 77:589–91. DOI: https://doi.org/10.1093/geronb/gbab055
Zhang M, Dai X, Chen G, Jin X, Zhao Y, Mei K, Wu Z, Huang H, 2023. Analysis of the distribution characteristics of prostate cancer and its environmental factors in China. Environ Sci Pollut Res Int 30:29349–68. DOI: https://doi.org/10.1007/s11356-022-24266-0
Zhu C, Wang DQ, Zi H, Huang Q, Gu JM, Li LY, Guo XP, Li F, Fang C, Li XD, Zeng XT, 2021. Epidemiological trends of urinary tract infections, urolithiasis and benign prostatic hyperplasia in 203 countries and territories from 1990 to 2019. Mil Med Res 8:64. DOI: https://doi.org/10.1186/s40779-021-00359-8
Zhu Y, Mo M, Wei Y, Wu J, Pan J, Freedland SJ, Zheng Y, Ye D, 2021. Epidemiology and genomics of prostate cancer in Asian men. Nat Rev Urol 18:282–301. DOI: https://doi.org/10.1038/s41585-021-00442-8
Ethics Approval
CRediT authorship contribution
Wen-Tong Ji and Jian-Long Wang, study design; Wen-Tong Ji and Yu-Sun Guo, drafting of the manuscript; Wen-Tong Ji and RT, data collection; Wen-Tong Ji, Yu-Sun Guo, and Xiang-Ze Wang, data analysis and interpretation; Xiang-Ze Wang and Run-Hua Tang, revision of the manuscript; Jian-Long Wang and Run-Hua Tang, supervision; Jian-Long Wang, obtaining funding.
Supporting Agencies
Data Availability Statement
All data generated or analyzed during this study are included in this published article.
How to Cite
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.
